CD8 PET Imaging in Metastatic Solid Tumours
Condition: Locally Advanced Solid Tumor · Sponsor: University Medical Center Groningen
About this study
This is a multi-center, single-arm trial designed to evaluate the safety and imaging characteristics of 89Zr-Df-crefmirlimab in patients with locally advanced or metastatic solid tumours prior to and during PD-1 antibody therapy.
This description comes directly from the study's public registry record.
Talk to the study team
Elisabeth GE de Vries, MD, PhD · +31 50 3612934 · e.g.e.de.vries@umcg.nl
Daan G. Knapen, MD · +31 50 3616161 · d.g.knapen@umcg.nl
Always discuss trial participation with your own doctor first.
Locations (4)
| VUMC | Amsterdam, Netherlands | Recruiting |
| University Medical Center Groningen | Groningen, Netherlands | Recruiting |
| Vall d'Hebron Institute of Oncology (VHIO) / Vall d'Hebron Institute Research (VHIR) | Barcelona, Spain | Not Yet Recruiting |
| University of Cambridge | Cambridge, United Kingdom | Not Yet Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06534190